FR3136375B1 - Microbulles lipidiques pour la délivrance ciblée d’actifs - Google Patents

Microbulles lipidiques pour la délivrance ciblée d’actifs

Info

Publication number
FR3136375B1
FR3136375B1 FR2205492A FR2205492A FR3136375B1 FR 3136375 B1 FR3136375 B1 FR 3136375B1 FR 2205492 A FR2205492 A FR 2205492A FR 2205492 A FR2205492 A FR 2205492A FR 3136375 B1 FR3136375 B1 FR 3136375B1
Authority
FR
France
Prior art keywords
microbubbles
relates
agent
active ingredients
microbubble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2205492A
Other languages
English (en)
Other versions
FR3136375A1 (fr
Inventor
Anthony Delalande
Chantal Pichon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Orléans
Original Assignee
Centre National de la Recherche Scientifique
University of Orléans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, University of Orléans filed Critical Centre National de la Recherche Scientifique
Priority to FR2205492A priority Critical patent/FR3136375B1/fr
Priority to PCT/FR2023/050819 priority patent/WO2023237842A1/fr
Priority to EP23736165.4A priority patent/EP4536284A1/fr
Priority to KR1020247041193A priority patent/KR20250043339A/ko
Priority to JP2024571890A priority patent/JP2025521199A/ja
Publication of FR3136375A1 publication Critical patent/FR3136375A1/fr
Application granted granted Critical
Publication of FR3136375B1 publication Critical patent/FR3136375B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Aggression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des microbulles optimisées, en particulier des microbulles lipidiques, pouvant être utilisés dans la prévention et le traitement de maladies ou encore le marquage. L’invention concerne en particulier une microbulle lipidique, comprenant au moins un composé cationique choisi parmi les lipophosphoramidates, les polyéthylénimines histidylées, et tout mélange de ceux-ci. La microbulle comprenant de préférence en outre au moins un agent choisi parmi un agent thérapeutique, un agent de ciblage, un agent de marquage, et toute combinaison de ceux-ci. L’invention se rapporte en outre à une méthode de production de cette microbulle. La présente invention concerne également une composition, notamment une composition pharmaceutique, et un kit, comprenant au moins une de ces microbulles. La présente invention porte en outre sur l’utilisation de ces microbulles, composition, kit, comme médicament ou comme agent de marquage.
FR2205492A 2022-06-08 2022-06-08 Microbulles lipidiques pour la délivrance ciblée d’actifs Active FR3136375B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2205492A FR3136375B1 (fr) 2022-06-08 2022-06-08 Microbulles lipidiques pour la délivrance ciblée d’actifs
PCT/FR2023/050819 WO2023237842A1 (fr) 2022-06-08 2023-06-08 Microbulles lipidiques pour la delivrance ciblee d'actifs
EP23736165.4A EP4536284A1 (fr) 2022-06-08 2023-06-08 Microbulles lipidiques pour la delivrance ciblee d'actifs
KR1020247041193A KR20250043339A (ko) 2022-06-08 2023-06-08 활성 성분의 표적화 전달을 위한 지질 마이크로버블
JP2024571890A JP2025521199A (ja) 2022-06-08 2023-06-08 有効成分の標的送達のための脂質マイクロバブル

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2205492 2022-06-08
FR2205492A FR3136375B1 (fr) 2022-06-08 2022-06-08 Microbulles lipidiques pour la délivrance ciblée d’actifs

Publications (2)

Publication Number Publication Date
FR3136375A1 FR3136375A1 (fr) 2023-12-15
FR3136375B1 true FR3136375B1 (fr) 2025-07-18

Family

ID=82693861

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2205492A Active FR3136375B1 (fr) 2022-06-08 2022-06-08 Microbulles lipidiques pour la délivrance ciblée d’actifs

Country Status (5)

Country Link
EP (1) EP4536284A1 (fr)
JP (1) JP2025521199A (fr)
KR (1) KR20250043339A (fr)
FR (1) FR3136375B1 (fr)
WO (1) WO2023237842A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3162989A1 (fr) * 2024-06-05 2025-12-12 Centre National De La Recherche Scientifique Microbulle comprenant un polymere ou copolymere fluore et un gaz fluore

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.

Also Published As

Publication number Publication date
KR20250043339A (ko) 2025-03-28
JP2025521199A (ja) 2025-07-08
FR3136375A1 (fr) 2023-12-15
WO2023237842A1 (fr) 2023-12-14
EP4536284A1 (fr) 2025-04-16

Similar Documents

Publication Publication Date Title
Hatzimouratidis et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015)
Misiak‐Galazka et al. What do we know about palmoplantar pustulosis?
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
Lee et al. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA59968B1 (fr) Composés de cyclobutyle dihydroquinoléine sulfonamide
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA26961A1 (fr) Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA30325B1 (fr) Composes qui potentialisent le recepteur ampa et leurs utilisations en medecine
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
MA27053A1 (fr) Beta-amino tetrahydroimidazo(1,2-a)pyrazines et tetrahydrotriazolo (4,3-a)pyrazines comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
TN2009000138A1 (fr) Biaryl-ether-urees
MY138289A (en) Pharmaceutical compositions
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA30723B1 (fr) Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA30296B1 (fr) Nouvelles amines
MA29573B1 (fr) Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20231215

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

CA Change of address

Effective date: 20250930

PLFP Fee payment

Year of fee payment: 5